Ayca Gucalp1,2, Tiffany A Traina3,4, Joel R Eisner5, Joel S Parker6,7, Sara R Selitsky7, Ben H Park8,9, Anthony D Elias10, Edwina S Baskin-Bey5, Fatima Cardoso11. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, Evelyn H. Lauder Breast Center, 300 East 66th Street, New York, NY, USA. gucalpa@mskcc.org. 2. Department of Medicine, Weill Cornell Medical College, 300 East 66th Street, New York, NY, 10065, USA. gucalpa@mskcc.org. 3. Department of Medicine, Memorial Sloan Kettering Cancer Center, Evelyn H. Lauder Breast Center, 300 East 66th Street, New York, NY, USA. 4. Department of Medicine, Weill Cornell Medical College, 300 East 66th Street, New York, NY, 10065, USA. 5. Innocrin Pharmaceuticals Inc., Durham, NC, USA. 6. Department of Genetics, University of North Carolina, Chapel Hill, NC, USA. 7. Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA. 8. Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. 9. Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA. 10. Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 11. Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal.
Abstract
PURPOSE: Male breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men and approximately 1% of all BCs worldwide. Because male BC is rare, not much is known about the disease, and treatment recommendations are typically extrapolated from data available from clinical trials enrolling female BC patients. METHODS: We review the epidemiology, risk factors, prognosis, and the varied molecular and clinicopathologic features that characterize male BC. In addition, we summarize the available data for the use of systemic therapy in the treatment of male BC and explore the ongoing development of targeted therapeutic agents for the treatment of this subgroup of BCs. RESULTS: There are important biological differences between male and female BC. Male BC is almost exclusively hormone receptor positive (+), including the androgen receptor (AR), and is associated with an increased prevalence of BRCA2 germline mutations, especially in men with increased risk for developing high-risk BC. Additional research is warranted to better characterize male BC. To accomplish this, a multi-national consortium approach, such as the International Male Breast Cancer Program, is needed in response to the scarcity of patients. This approach allows the pooling of information from a large number of men with BC and the creation of registries for future therapeutic-focused clinical trials. CONCLUSIONS: Given the unique biology of BC in men, promising new therapeutic targets are currently under investigation, including the use of poly-ADP-ribose polymerase inhibitors or AR-targeted agents either as monotherapy or in combination with other agents.
PURPOSE:Male breast cancer (BC) is rare, representing approximately 1% of cancers that occur in men and approximately 1% of all BCs worldwide. Because male BC is rare, not much is known about the disease, and treatment recommendations are typically extrapolated from data available from clinical trials enrolling female BC patients. METHODS: We review the epidemiology, risk factors, prognosis, and the varied molecular and clinicopathologic features that characterize male BC. In addition, we summarize the available data for the use of systemic therapy in the treatment of male BC and explore the ongoing development of targeted therapeutic agents for the treatment of this subgroup of BCs. RESULTS: There are important biological differences between male and female BC. Male BC is almost exclusively hormone receptor positive (+), including the androgen receptor (AR), and is associated with an increased prevalence of BRCA2 germline mutations, especially in men with increased risk for developing high-risk BC. Additional research is warranted to better characterize male BC. To accomplish this, a multi-national consortium approach, such as the International Male Breast Cancer Program, is needed in response to the scarcity of patients. This approach allows the pooling of information from a large number of men with BC and the creation of registries for future therapeutic-focused clinical trials. CONCLUSIONS: Given the unique biology of BC in men, promising new therapeutic targets are currently under investigation, including the use of poly-ADP-ribose polymerase inhibitors or AR-targeted agents either as monotherapy or in combination with other agents.
Entities:
Keywords:
Androgen and estrogen biosynthesis inhibition; Androgen receptor; Anti-androgen; Biomarkers; Endocrine therapy; Male breast cancer
Authors: Jennifer K Plichta; Yi Ren; Caitlin E Marks; Samantha M Thomas; Rachel A Greenup; Laura H Rosenberger; Oluwadamilola M Fayanju; Susan G R McDuff; E Shelley Hwang; Jeremy Force Journal: Ann Surg Oncol Date: 2020-07-23 Impact factor: 5.344
Authors: Ainhoa Arana Echarri; Mark Beresford; John P Campbell; Robert H Jones; Rachel Butler; Kenneth J Gollob; Patricia C Brum; Dylan Thompson; James E Turner Journal: Front Immunol Date: 2021-02-01 Impact factor: 7.561
Authors: Eduarda Hiss Faria; Dirrieh Kim; Rafaela Melo Sisconetto; Vitória Flávia Melo Cucio; Pedro Paulo Guerreiro Dos Reis Ferreira; Bruna Silva Rodrigues Alves; Ígor Mendes Macedo Mendonça; Maite Rocha Oliveira; Anna Leticia Barbosa Vicente; Jeniffer Cristine Alves; Douglas Reis Abdalla Journal: Eur J Breast Health Date: 2021-10-04
Authors: Kamal Eldin Ahmed Abdelsalam; Mohammed Asad; Monjid Ahmed Ibrahim Ahmed; Syed Mohammed Basheeruddin Asdaq; Yahya Mohzari; Ahmed Alrashed; NajwaJilan Alghamdi; Kholoud Nasser Alrami; Wael Ahmed Alharbi Journal: Int J Environ Res Public Health Date: 2021-05-01 Impact factor: 3.390
Authors: Susana Nunes Silva; Bruno Costa Gomes; Saudade André; Ana Félix; António Sebastião Rodrigues; José Rueff Journal: Breast Cancer Res Treat Date: 2021-05-03 Impact factor: 4.872